

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Zontivity (vorapaxar)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zontivity (vorapaxar)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Zontivity (vorapaxar) may be approved if the following criteria are met:

- I. Individual has a history of myocardial infarction (MI) or peripheral arterial disease (PAD); **AND**
- II. Individual is using to reduce thrombotic cardiovascular events (such as cardiovascular death, MI, stroke, and need for urgent coronary revascularization); **AND**
- III. Individual is using in combination with aspirin and/or clopidogrel.

Requests for Zontivity (vorapaxar) may not be approved in individuals with the following:

- I. History of stroke, transient ischemic attack, or intracranial hemorrhage; **OR**
- II. Active pathologic bleeding; **OR**
- III. Individual with severe hepatic impairment (Child Pugh Class C).

Note:

Zontivity (vorapaxar) has a black box warning for bleeding risk. Antiplatelet agents can cause significant, sometimes fatal, bleeding. Do not use antiplatelet agents in individuals with active pathological bleeding or a history of intracranial hemorrhage, and do not start antiplatelet agents in individuals undergoing urgent coronary artery bypass graft surgery (CABG). If possible, manage bleeding without discontinuing the antiplatelet agent as stopping treatment increases the risk of subsequent cardiovascular events.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: December 26, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

3. Kernan WN, Ovbiagele B, Black HR et. al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association (AHA/ASA). *Stroke*. 2014;45(7):2160-2236.
4. Lansberg MG, O'Donnell MJ, Khatri P et. al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e601S-e636S.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.